BofA lowered the firm’s price target on CureVac (CVAC) to $2 from $2.50 and keeps an Underperform rating on the shares. Q1 results highlighted the progression of the pipeline in early-stage clinical studies, but the firm sees work to be done to prove the value of the pipeline and awaits clarity on the patent dispute situation, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- CureVac N.V. Reports Q1 2025 Financial Results Amid Strategic Restructuring
- CureVac Reports Q1 2025 Financial Results Amid Revenue Decline
- CureVac Reports Q1 2025 Financials and Advances in Oncology Pipeline
- CureVac reports Q1 revenue EUR 0.9M vs. EUR 12.4M last year
- CureVac reaffirms expected cash runway into 2028